Abstract
During the last years an increasing number of patients with high perioperative risk and decreased left ventricular function are referred to cardiac and non-cardiac surgery. In this subgroup of patients, heart failure is the major cause of perioperative morbidity and mortality. In order to prevent and treat this type of complications several therapeutic attempts have been tried involving intra aortic balloon pump and inotropic agents infusion (such as beta-adrenergic agonists and phosphodiesterase inhibitors)
Levosimendan is new inotropic agent; it is a calcium-sensitising inotropic agent and a vasodilator used in the treatment of heart failure. In the last ten years several reports have been published on levosimendan. The inotropic efficacy of levosimendan is dose-dependent and equal or even superior to any of the other commercially available inotropic agents.
The aim of the present review is to describe experimental and clinical effects of perioperative treatment with levosimendan.
Keywords: Levosimendan, heart failure, cardiac surgery.
Current Pharmaceutical Design
Title:Levosimendan Preoperative
Volume: 19 Issue: 22
Author(s): Andrea Rognoni, Alessandro Lupi, Chiara Cavallino, Alessia Veia, Sara Bacchini, Roberta Rosso, Gioel Gabrio Secco and Angelo Sante Bongo
Affiliation:
Keywords: Levosimendan, heart failure, cardiac surgery.
Abstract: During the last years an increasing number of patients with high perioperative risk and decreased left ventricular function are referred to cardiac and non-cardiac surgery. In this subgroup of patients, heart failure is the major cause of perioperative morbidity and mortality. In order to prevent and treat this type of complications several therapeutic attempts have been tried involving intra aortic balloon pump and inotropic agents infusion (such as beta-adrenergic agonists and phosphodiesterase inhibitors)
Levosimendan is new inotropic agent; it is a calcium-sensitising inotropic agent and a vasodilator used in the treatment of heart failure. In the last ten years several reports have been published on levosimendan. The inotropic efficacy of levosimendan is dose-dependent and equal or even superior to any of the other commercially available inotropic agents.
The aim of the present review is to describe experimental and clinical effects of perioperative treatment with levosimendan.
Export Options
About this article
Cite this article as:
Rognoni Andrea, Lupi Alessandro, Cavallino Chiara, Veia Alessia, Bacchini Sara, Rosso Roberta, Secco Gioel Gabrio and Sante Bongo Angelo, Levosimendan Preoperative, Current Pharmaceutical Design 2013; 19 (22) . https://dx.doi.org/10.2174/1381612811319220005
DOI https://dx.doi.org/10.2174/1381612811319220005 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Angiogenesis-regulating microRNAs and Ischemic Stroke
Current Vascular Pharmacology Torasemide in Hypertension and Heart Failure: Re-inventing Loop Diuretic Therapy?
Current Pharmaceutical Design Incorporation of Targeted Agents in the Management of Patients with Advanced Gastric Cancer
Current Medicinal Chemistry Antiproliferative Efficacy of Angiotensin II Receptor Blockers in Prostate Cancer
Current Cancer Drug Targets Apoptotic and Anti-Angiogenic Effects of Benzimidazole Compounds: Relationship with Oxidative Stress Mediated Ischemia/Reperfusion Injury in Rat Hind Limb
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cardiovascular Risk, Inflammation and Physical Activity in Rheumatoid Arthritis
Current Rheumatology Reviews Matrix Metalloproteinases: Drug Targets for Myocardial Infarction
Current Drug Targets Hypertension and Concurrent Arrhythmias
Current Pharmaceutical Design The Role of the Novel Adipocyte-Derived Protein Adiponectin in Human Disease: An Update
Mini-Reviews in Medicinal Chemistry Incretins Yesterday, Pleiotropic Gastrointestinal Hormones Today:Glucagon-Like Peptide-1 (GLP-1) and Glucose-ependent Insulinotropic Polypeptide (GIP)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Eosinophilopoiesis at the Cross-Roads of Research on Development, Immunity and Drug Discovery
Current Medicinal Chemistry Future Therapeutic Strategies in Inflammatory Cardiomyopathy: Insights from the Experimental Autoimmune Myocarditis Model
Cardiovascular & Hematological Disorders-Drug Targets A Comprehensive and Contemporary Review on Immunosuppression Therapy for Heart Transplantation
Current Pharmaceutical Design Antisense Oligonucleotides for the Treatment of Dyslipidemia
Current Pharmaceutical Design Need for Ongoing Anti Arrhythmic Drugs After Ablation of Atrial Fibrillation. Review
Recent Patents on Cardiovascular Drug Discovery Contribution of ALDH2 Polymorphism to Alcoholism-Associated Hypertension
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Dronedarone: A Safety Comparison to Amiodarone
Current Drug Safety Protein Degradation by the Ubiquitin-Proteasome Pathway and Organ Fibrosis
Current Medicinal Chemistry Pharmacokinetics of Biotech Drugs: Peptides, Proteins and Monoclonal Antibodies
Current Drug Metabolism Cardiac Amyloid - A Hidden Contributor to Cardiac Dysfunction Following Cardiac Surgery: Case Report and Literature Review
Current Cardiology Reviews